Key result
Novel ACAT inhibitor Compound 25 lowers plasma cholesterol by ~73% in hypercholesterolemic animal models.
Answers are grounded in this paper and cite their sources.
We have synthesized a series of N-phenyl-N'-aralkyl and N-phenyl-N'-(1-phenylcycloalkyl)ureas as inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). This intracellular enzyme is thought to be responsible for the esterification of dietary cholesterol; hence inhibition of this enzyme could reduce diet-induced hypercholesterolemia. For this series of compounds, the in vitro ACAT inhibitory activity was improved by increasing the bulk of the 2,6-substituents on the phenyl ring. Additionally, we found that spacing of the aromatic rings was critical for ACAT inhibitory activity. A phenyl ring five atoms away from the requisite 2,6-diisopropylphenyl moiety was optimal for in vitro activity. Substitution alpha to the N'-phenyl moiety enhanced in vitro potency. In the case of phenylcycloalkyl ureas, ACAT inhibitory activity was independent of the size of the cycloalkyl ring. From this series of analogs, compound 25, which had excellent in vitro potency for inhibiting ACAT, was found to lower plasma cholesterol by 73% in vivo when administered in the diet at 50 mg/kg in an animal model of hypercholesterolemia. In this model, compound 25 lowered plasma cholesterol dose dependently and was as efficacious as the Lederle ACAT inhibitor CL 277082.
No takes yet. Share an insight, caveat, or question.
Trivedi et al. (1993) studied hypercholesterolemia. Compound 25 (urea ACAT inhibitor) vs. Lederle ACAT inhibitor CL 277082 was evaluated on plasma cholesterol reduction (73% reduction). Compound 25, a novel urea ACAT inhibitor, lowered plasma cholesterol by 73% when administered in the diet at /kg in an animal model of hypercholesterolemia.
Synapse has enriched 10 related papers. Consider them for comparative context: